Effectiveness and Safety of Concurrent Use of First-Line Antiretroviral and Antituberculous Drugs in Rwanda
Table 3
Association between various factors and clinical outcomes.
Variable
HIV-alone ()
HIV/TB ()
Improved
Unimproved
Died
Sign
Improved
Unimproved
Died
Sign
(%)
(%)
(%)
value
(%)
(%)
(%)
value
Gender
Male
17 (89.5)
0
2 (10.5)
0.116
7 (26.9)
10 (38.5)
9 (34.6)
0.037
Female
30 (73.2)
8 (19.5)
3 (7.3)
16 (47.1)
15 (44.1)
3 (8.8)
Age (years)
<40
36 (83.7)
2 (4.7)
5 (11.6)
0.004
21 (39.6)
22 (41.5)
10 (18.9)
0.782
>40
11 (64.7)
6 (35.3)
0
2 (28.6)
3 (42.9)
2 (28.6)
Weight (kg)
Gained
5 (100)
0
0
0.009
0
0
0
0.032
Lost
42 (83.3)
8 (4.8)
5 (11.9)
23 (38.3)
25 (41.7)
12 (20.0)
CD4 (cells/mm3)
Gained
42 (76.4)
8 (14.5)
5 (9.1)
0.001
3 (27.3)
5 (45.4)
3 (27.3)
0.000
Lost
4 (100)
0
0
20 (40.8)
20 (40.8)
9 (18.4)
ART length
<1 year
9 (75.0)
0
3 (25.0)
0.107
6 (100)
0
0
0.003
1–5 years
25 (78.2)
5 (15.6)
2 (6.2)
11 (36.7)
10 (33.3)
9 (30.0)
>5 years
13 (81.2)
3 (18.8)
0
6 (25.0)
15 (62.5)
3 (12.5)
Column percent
47 (78.4)
8 (13.3)
5 (8.3)
23 (38.4)
25 (41.6)
12 (20)
Total between row percentage is calculated by dividing the frequency by 60 patients in each group. Within row percentage is calculated by dividing the frequency by the total frequency of each regimen alone. Sign: Pearson Chi-square.
